EU and Japan in mutual recognition agreement
A mutual recognition agreement on good pharmaceutical manufacturing practice struck between Japan and the European Union (EU) will come into force on May 29, allowing certain medicines to be traded then sold without additional testing or certification.
A mutual recognition agreement on good pharmaceutical manufacturing practice struck between Japan and the European Union (EU) will come into force on May 29, allowing certain medicines to be traded then sold without additional testing or certification.
These include standard, homeopathic and vitamin treatments as listed in the agreement's annexe, and the scope will be reviewed in the future. The EU-Japan pharmaceutical trade is worth around €10bn annually, said the European Commission.